Nevirapine

Generic Name: Nevirapine

Brand Names: Viramune

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₄N_₄O

CAS Number: 129618-40-2

Unique Ingredient Identifier: 99DK7FVK1H

Background: A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.

Indication: For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV

Phase 4

Completed

Conditions: Acquired Immunodeficiency Syndrome

First Posted Date: 2005-09-05

Last Posted Date: 2013-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53

Registration Number: NCT00144157

Locations: 🇿🇦
Boehringer Ingelheim Investigational Site, Soweto, South Africa

An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects

Phase 4

Completed

Conditions: HIV Infections
Metabolism, Lipids

First Posted Date: 2005-09-05

Last Posted Date: 2017-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT00144261

Locations: 🇳🇱
1100.1426.02 Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇳🇱
1100.1426.01 Academic Medical Centre, Amsterdam, Netherlands
🇬🇧
1100.1426.44001 Boehringer Ingelheim Investigational Site, London, United Kingdom

A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions

Phase 4

Completed

Conditions: HIV Infections
Hepatic Insufficiency

First Posted Date: 2005-09-05

Last Posted Date: 2023-12-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 51

Registration Number: NCT00144248

Locations: 🇺🇸
Albany Medical College, MC 142, Albany, New York, United States
🇫🇷
Hopital Pitie Salpetriere, Paris, France
🇺🇸
Boehringer Ingelheim Investigational Site, Providence, Rhode Island, United States

and more 3 locations

2NN & CHARM Long-Term Follow-up Study

Phase 4

Completed

Conditions: HIV Infections

First Posted Date: 2005-08-09

Last Posted Date: 2007-04-30

Lead Sponsor: International Antiviral Therapy Evaluation Center

Target Recruit Count: 763

Registration Number: NCT00127972

Locations: 🇦🇺
Holdsworth House Medical Practice, Darlinghurst, Australia

Pediatric Nevirapine Resistance Study

Phase 3

Conditions: AIDS
HIV Infections

First Posted Date: 2005-07-08

Last Posted Date: 2007-06-29

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Target Recruit Count: 250

Registration Number: NCT00117728

Locations: 🇿🇦
Coronation Hospital, Johannesburg, South Africa

Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Nevirapine
Drug: AZT
Drug: NVP
Drug: NVP and AZT
Drug: NVP+AZT

First Posted Date: 2005-06-24

Last Posted Date: 2014-03-07

Lead Sponsor: Johns Hopkins Bloomberg School of Public Health

Target Recruit Count: 3300

Registration Number: NCT00115648

Locations: 🇲🇼
College of Medicine, Blantyre, Malawi

Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Didanosine, enteric-coated
Drug: Lopinavir/ritonavir
Drug: Nevirapine
Drug: Zidovudine

First Posted Date: 2005-05-02

Last Posted Date: 2021-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 175

Registration Number: NCT00109590

Locations: 🇹🇭
Siriraj Hospital Mahidol University CRS, Bangkok, Bangkoknoi, Thailand
🇹🇭
Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand
🇹🇭
Chiangrai Prachanukroh Hospital CRS, Chiangrai, Thailand

and more 4 locations

Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Abacavir sulfate
Drug: Didanosine
Drug: Efavirenz
Drug: Lamivudine
Drug: Lopinavir/Ritonavir
Drug: Nevirapine
Drug: Zidovudine

First Posted Date: 2005-02-07

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 377

Registration Number: NCT00102960

NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Emtricitabine
Drug: Emtricitabine/Tenofovir disoproxil fumarate
Drug: Nevirapine
Drug: Lopinavir/Ritonavir
Drug: Tenofovir disoproxil fumarate

First Posted Date: 2004-08-06

Last Posted Date: 2018-10-12

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 745

Registration Number: NCT00089505

Locations: 🇿🇦
University of Witwatersrand, Johannesburg, South Africa
🇧🇼
The Gaborone BHP Study Clinic, Bontleng, Gaborone, Botswana
🇿🇲
Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia

and more 8 locations

Three Month Course of Anti-HIV Medications for People Recently Infected With HIV

Not Applicable

Withdrawn

Conditions: HIV Infections

First Posted Date: 2004-07-13

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00087464

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy